{ "@context": "https://orbyd.app/schemas/dossier.v1.json", "ticker": "NUVL", "name": "Nuvalent, Inc.", "url": "https://orbyd.app/dossiers/NUVL/", "json_url": "https://orbyd.app/dossiers/NUVL.json", "status": "DORMANT", "current_conviction": "LOW", "graded_conviction": null, "archetype": { "code": "a5", "n": 5 }, "current_thesis": "GSK's $124/share all-cash acquisition has closed: the tender expired 2026-07-14 with ~91.3% of shares tendered and accepted for payment, satisfying the minimum condition and triggering a Section 251(h) merger, Nasdaq delisting and SEC deregistration. The narrative is fully resolved — no US-listed equity remains to trade.", "invalidation_trigger": "A daily close below $124 (the fixed cash consideration now being paid out) would be the only sign of a payment or delisting disruption; with ~91.3% of shares tendered and accepted for payment as of 2026-07-14 and a Section 251(h) merger underway, that outcome is effectively foreclosed and no directional trade remains.", "catalyst_date": null, "outcome": "OPEN", "outcome_date": null, "invalidation_fired": null, "themes": [ "precision-biotech-therapeutics", "oncology-immunology" ], "tags": [], "sources": [], "notes": [ "Avoid fresh momentum entries — asymmetry is inverted (thin spread to $124 vs full deal-break downside). Only a competing bid >$124 reopens a directional trade.", "Lead candidates: zidesamtinib (NVL-520, ROS1) and neladalkib (NVL-655, ALK) for resistance-mutant NSCLC — strategic fit underpins deal-close probability.", "GSK acquisition CLOSED — minimum tender condition and all offer conditions satisfied.", "Section 251(h) back-end merger being effected WITHOUT a shareholder vote; Nasdaq delisting (Form 25) + SEC deregistration (Form 15) underway — the tradeable instrument is being retired. No US-listed equity to trade going forward.", "Aggregate equity value ~$10.6B; $124 was ~40% premium to the pre-announcement close. No competing bid above $124 emerged through the tender window.", "DEAD for a momentum book. Residual narrative is read-through to peer resistance-mutant NSCLC / precision-oncology takeout candidates, not NUVL itself.", "Lead assets zidesamtinib (NVL-520, ROS1) and neladalkib (NVL-655, ALK) now sit inside GSK's oncology franchise — the strategic-fit thesis that underpinned close-probability played out.", "Do not carry the elapsed 2026-07-23 tender-expiry estimate forward; actual expiry was 2026-07-14. No forward catalyst remains." ], "body_markdown": "## Current Thesis\nThe precision-oncology momentum leg in NUVL is finished. GSK's all-cash tender offer at $124/share, commenced 2026-06-24, expired one minute after 11:59 p.m. roughly 91.3% of shares outstanding — validly tendered and irrevocably accepted for payment. The minimum tender condition and all other offer conditions were satisfied. GSK, through GlaxoSmithKline LLC and Harmony Row Acquisition Co., now controls enough of the company to push through a Section 251(h) back-end merger with no shareholder vote, converting remaining shares to the same $124 cash. Nasdaq delisting and SEC deregistration follow. The aggregate equity value is about $10.6 billion. For a book that trades accelerating narratives, there is nothing left here: the instrument itself is being retired, and no US-listed equity will remain to trade.\n\n## Bull Case\n- **Cash certainty was fully realized.** The 2026-07-14 expiry cleared the minimum tender condition with ~91.3% of shares in;\n- **Back-end merger is mechanical.** Because the purchaser crossed the ownership threshold, the Section 251(h) merger completes without a stockholder meeting — no vote to whip, no litigation gate, no financing contingency left to clear.\n- **Strategic fit that underpinned close-probability held up.** Nuvalent's franchise — zidesamtinib (NVL-520, brain-penetrant ROS1) and neladalkib (NVL-655, ALK), both aimed at resistance mutations in NSCLC — slotted into GSK's oncology buildout exactly as the June thesis assumed, and the deal closed on schedule.\n\n## Bear Case\n- **$124 is terminal, and now literal.** The fixed cash consideration is the last print. There is no forward equity to compound and no parabolic leg possible once the shares deregister.\n- **No topping bid ever came.** Through the entire 2026-06-24 to 2026-07-14 tender window, nothing above $124 emerged. The ceiling that six June downgrades snapped their targets to was the exit price.\n- **The tradeable name disappears.** Post-merger delisting (Form 25) and SEC deregistration (Form 15) remove the instrument; any capital pointed here after 2026-07-14 is buying a husk pending cash conversion, with zero directional expression.\n\n## Setup & Price Structure\nThe whole move happened in the 2026-06-24 announcement gap; everything since was arbitrageurs absorbing float at a hair below the deal price. Price pinned at/just under $124 into the 2026-07-14 expiry, volume decayed through the window rather than expanding, and momentum oscillators carry no information on a price-capped, soon-delisted security. There is no trend, no base, no continuation to trade — a flat tape counting down to deregistration. A fresh entry buys a sub-1% residual to $124 against the friction of a delisting process, which is not a setup a narrative operator has any business in.\n\n## Catalyst Calendar (next 30 days)\n\n- **Following the merger (est., within weeks):** Nasdaq delisting via Form 25 and SEC deregistration via Form 15 — the end of the listed instrument. No forward directional catalyst exists.\n\n## Elapsed catalysts\n\n- **2026-07-14 (elapsed):** Tender offer and withdrawal rights expired; minimum condition satisfied. *(passed 26d ago)*\n- **~2026-07-15 onward (est., days after expiry):** Section 251(h) merger completion — untendered shares converted into the right to receive $124 cash; Nuvalent becomes a wholly owned GSK subsidiary. *(passed 25d ago)*\n\n## What Would Change Our Mind\n- A daily close below $124 (the fixed cash consideration now being paid out) is the only price event that could reintroduce standalone-valuation risk, and with ~91.3% of shares tendered and accepted for payment as of 2026-07-14 and a Section 251(h) merger already underway, that outcome is effectively foreclosed.\n- The only way a directional trade reopens is an off-book surprise — a court injunction unwinding the accepted-for-payment shares, or a regulatory reversal — none of which is on any visible docket.\n- The live narrative has migrated off NUVL entirely: it now lives in whichever peer screens as the next resistance-mutant NSCLC takeout, not in a name that is deregistering.\n\n## Correlation Notes\nGSK's $10.6 billion cash close signals big-pharma appetite for late-line, resistance-mutant precision oncology, and the cleanest read-through is to peer clinical-stage ROS1/ALK and targeted-NSCLC developers that could screen as the next strategic target — that is where residual narrative velocity sits, on the acquirer-appetite theme rather than the acquired name. As a security, NUVL now behaves like cash: essentially zero beta to XBI/IBB or the broad tape through delisting, since price is fixed at the $124 consideration. Any correlation NUVL once carried to the clinical-stage-oncology and precision-biotech complex severed at the 2026-06-24 announcement gap and does not return.", "first_seen": "2026-07-02", "last_analyzed": "2026-07-25T07:38:29+00:00", "last_synthesized": "2026-07-25", "last_update_source": "watchlist_research", "license": "Content © orbyd. Cite the canonical URL." }